Easom Eric 4

What Happened

• Eric Easom, CEO of AN2 Therapeutics (ANTX), was awarded equity on February 20, 2026: 112,250 restricted stock units (RSUs) and 224,500 RSU-style derivative awards (total 336,750 units). The reported acquisition price for these awards is $0 (typical for RSU grants); they are compensation awards rather than open‑market purchases or sales.

Key Details

• Transaction date: February 20, 2026; filing date: February 23, 2026 (timely).
• Reported price: $0.00 per share (award/grant).
• Total units granted/reported: 112,250 (RSUs) + 224,500 (derivative RSUs) = 336,750.
• Shares owned after transaction: not specified in the provided excerpt.
• Relevant footnotes from the filing:
  • F1: The 112,250 RSUs vest 1/4 annually over four years beginning January 1, 2026, subject to continuous service.
  • F2: The derivative balance includes RSU balances that vest 1/4 annually over four years from Jan 1, 2025 (145,250 RSUs) and Jan 1, 2024 (99,000 RSUs), subject to continuous service.
  • F3–F5: Certain common shares are held in named trusts (Easom Living Trust and two irrevocable trusts).
  • F6: Option vesting schedule referenced elsewhere in the filing: 1/48th monthly over four years from Jan 1, 2026.
• Filing timeliness: Filed Feb 23, 2026 for a Feb 20, 2026 transaction — within the standard two business‑day reporting window.

Context

• These awards are compensation RSUs with multi‑year vesting and a continuous‑service requirement, meaning the units convert to actual shares only as they vest. Such grants are common executive compensation and do not involve an immediate cash purchase or sale of stock. Derivative/RSU entries indicate future entitlement to shares rather than exercised options or immediate transfers.